Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Testosterone Cypionate

FDA-approved product (injectable, injection), marketed as Azmiro, Depo-Testosterone, Testosterone Cypionate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Testosterone Cypionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Hypogonadism
  • Hypogonadotropic hypogonadism
  • Klinefelter's syndrome
  • Neoplasm
  • Orchitis
  • Physiological sexual disorder
  • Sexual dysfunction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
3-oxoandrosten (4) derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Testosterone Cypionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Testosterone Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

    NCT07742553 · start 2027-10-01

    Registered record
    Registry ID
    NCT07742553
    Conditions
    Spinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord; Spinal Cord Contusion; Spinal Cord Trauma; Trauma, Nervous System; Wounds and Injuries; Spinal Cord Compression; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male
    Interventions
    testosterone cypionate; finasteride; placebo injection; placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-10-01
    Completion
    2032-03-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord; Spinal Cord Contusion +10 more
    Interventiontestosterone cypionate; finasteride; placebo injection; placebo pill
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

    NCT07278362 · start 2026-08-31

    Registered record
    Registry ID
    NCT07278362
    Conditions
    Prostate Cancer; Hypogonadism, Male
    Interventions
    Testosterone cypionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-31
    Completion
    2032-05-31
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Hypogonadism, Male
    InterventionTestosterone cypionate
    PhasePhase 4
    Registry statusNot yet recruiting

  • Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

    NCT07568574 · start 2026-03-12

    Registered record
    Registry ID
    NCT07568574
    Conditions
    Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    Interventions
    Testosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone); Testosterone Gel; Methenolone Enanthate (Primobolan); Nandrolone Decanoate (Deca-Durabolin); Estradiol Patch; Estradiol Capsule; Progesterone Cream; Progesterone Capsule; Human Growth Hormone (hGH); EPO Darbepoetin (Aranesp); Meldonium; Modafinil; Mixed amphetamine salts (Adderall); Clomiphene; Anastrozole; Levothyroxine; Liothyronine; hCG; hMG; Atorvastatin; Rosuvastatin; Bisoprolol; Nebivolol; Metoprolol; Propranolol; Lisinopril; Enalapril; Furosemide; Chlorothiazide; Cabergoline; Metformin; Basal Insulin Glargine (long-acting); Telmisartan; Losartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-03-12
    Completion
    2033-03-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    InterventionTestosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone) +33 more
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

    NCT07142551 · start 2026-03-09

    Registered record
    Registry ID
    NCT07142551
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    Testosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; Darolutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-03-09
    Completion
    2034-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionTestosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; Darolutamide
    PhasePhase 2
    Registry statusRecruiting

  • Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

    NCT07476001 · start 2026-03-03

    Registered record
    Registry ID
    NCT07476001
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    Testosterone cypionate (Tc); ADT with Luteinizing hormone-releasing hormone (LHRH) analog; PSMA-617
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-03-03
    Completion
    2027-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionTestosterone cypionate (Tc); ADT with Luteinizing hormone-releasing hormone (LHRH) analog; PSMA-617
    PhasePhase 2
    Registry statusRecruiting

  • Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men

    NCT07328542 · start 2026-02

    Registered record
    Registry ID
    NCT07328542
    Conditions
    Hypogonadism, Male
    Interventions
    Testosterone Cypionate Injection 200 mg/mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-02
    Completion
    2027-08
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism, Male
    InterventionTestosterone Cypionate Injection 200 mg/mL
    PhasePhase 4
    Registry statusNot yet recruiting

  • Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version

    NCT07092527 · start 2025-12-05

    Registered record
    Registry ID
    NCT07092527
    Conditions
    Transgenderism; Reproductive Issues
    Interventions
    Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-12-05
    Completion
    2028-11-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransgenderism; Reproductive Issues
    InterventionTestosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
    PhasePhase 4
    Registry statusRecruiting

  • The COSMYC Trial (COmbined Suppression of MYC)

    NCT06922318 · start 2025-08-19

    Registered record
    Registry ID
    NCT06922318
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    ZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-19
    Completion
    2031-08-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    PhasePhase 2
    Registry statusRecruiting

  • Androgen Effects on the Reproductive Neuroendocrine Axis

    NCT06450405 · start 2025-02-26

    Registered record
    Registry ID
    NCT06450405
    Conditions
    Transgenderism; Reproductive Issues
    Interventions
    Testosterone Cypionate 50 MG/ML Injectable Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2025-02-26
    Completion
    2025-03-03
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransgenderism; Reproductive Issues
    InterventionTestosterone Cypionate 50 MG/ML Injectable Solution
    PhasePhase 4
    Registry statusTerminated

  • The Anabolic Effect of Testosterone on Pelvic Floor Muscles

    NCT06111209 · start 2025-02-15

    Registered record
    Registry ID
    NCT06111209
    Conditions
    Stress Urinary Incontinence; Menopause
    Interventions
    Testosterone cypionate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-02-15
    Completion
    2027-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Urinary Incontinence; Menopause
    InterventionTestosterone cypionate; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • Peri-Operative Testosterone Administration in Primary Hip Arthroscopy

    NCT06462482 · start 2025-01

    Registered record
    Registry ID
    NCT06462482
    Conditions
    Femoro Acetabular Impingement
    Interventions
    Nandrolone Decanoate; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-01
    Completion
    2026-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemoro Acetabular Impingement
    InterventionNandrolone Decanoate; Saline
    PhasePhase 4
    Registry statusNot yet recruiting

  • Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

    NCT06305598 · start 2024-12-19

    Registered record
    Registry ID
    NCT06305598
    Conditions
    Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Biopsy; Bone Scan; Computed Tomography; Leuprolide Acetate; Magnetic Resonance Imaging; Survey Administration; Testosterone Cypionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2024-12-19
    Completion
    2028-03-09
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionBiopsy; Bone Scan; Computed Tomography; Leuprolide Acetate +3 more
    PhasePhase 1
    Registry statusActive not recruiting

  • TESTO-TRIAL: Use of Testosterone in Critically Ill Patients

    NCT06592144 · start 2024-09-09

    Registered record
    Registry ID
    NCT06592144
    Conditions
    Weaning Failure; Muscle Weakness; Mechanical Ventilation Complication; ICU Acquired Weakness; Mobility Limitation
    Interventions
    Testosterone cypionate (200mg/3ml); Sesame oil (3ml)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-09-09
    Completion
    2026-11-02
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWeaning Failure; Muscle Weakness; Mechanical Ventilation Complication; ICU Acquired Weakness +1 more
    InterventionTestosterone cypionate (200mg/3ml); Sesame oil (3ml)
    PhasePhase 4
    Registry statusActive not recruiting

  • Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

    NCT06039371 · start 2024-05-21

    Registered record
    Registry ID
    NCT06039371
    Conditions
    Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Biopsy Procedure; Biospecimen Collection; Bone Scan; Carboplatin; Computed Tomography; Etoposide; Quality-of-Life Assessment; Questionnaire Administration; Testosterone Cypionate; Radioconjugate; Dual X-ray Absorptiometry; Gallium Ga 68-PSMA-617; Positron Emission Tomography; Single Photon Emission Computed Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-21
    Completion
    2028-11-01
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionBiopsy Procedure; Biospecimen Collection; Bone Scan; Carboplatin +10 more
    PhasePhase 2
    Registry statusRecruiting

  • Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

    NCT06100705 · start 2023-12-20

    Registered record
    Registry ID
    NCT06100705
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    Testosterone Cypionate; Sipuleucel-T
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-12-20
    Completion
    2028-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionTestosterone Cypionate; Sipuleucel-T
    PhasePhase 2
    Registry statusRecruiting